BioSpace News Archive

CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced that it has also acquired TX Services, LLC, provider of TX Connect, as part of its acquisition of TransChart in January 2021.

Bio-Techne Corporation (NASDAQ: TECH), a leading provider of proteins, antibodies and cytokines today announced that its sites in Abingdon, Langley, Rennes and Wiesbaden received ISO 14001:2015 certification for Environmental Management Systems.

Milestone Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, announced that Joseph Oliveto, President and Chief Executive Officer, will present at the following investor conferences:

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, announced today that it has launched a strategic development collaboration and exclusive supply agreement with PureForm Global, Inc.

-U.S. Food and Drug Administration (FDA) filing of a Biologics License Application (BLA) and Priority Review for teplizumab for the delay or prevention of clinical type 1 diabetes in at-risk individuals; PDUFA goal date of July 2, 2021-

ESSA Pharma Inc. (Nasdaq: EPIX) ), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company has entered into a clinical collaboration and supply agreement with Astellas Pharma

Encouraging signals of anti-tumor activity demonstrated across COM701 Phase 1 combination and monotherapy studies with durable responses, including a complete response, in tumor types typically unresponsive to checkpoint inhibitors

CTP-543 Phase 3 Program Advancing in Alopecia Areata; THRIVE-AA2, the Second CTP‑543 Phase 3 Trial, to Initiate 1H2021 CTP-543 Long-Term Data Presented at EADV Show Hair Regrowth was Maintained or Improved in Patients with Alopecia Areata, Expanding Previous Phase 2 Results Conference Call and Webcast Scheduled Today at 8:30 a.m. ET

ReForm Biologics today announced it will expand its focus to develop a new generation of bio-innovative biologic medicines in-house to improve patient access, safety and convenience. As well, James (Jim) Sherblom has joined the board of directors of ReForm as chairman to lead the shift in strategy.

New venture is led by the former AveXis management team and was created in collaboration with Deerfield Management, which funded the Series A financing and provides access to established academic institutions for future pipeline programs The current pipeline utilizes the proven and well-characterized AAV9 vector to target diseases with significant unmet need, including galactosemia, genetic causes of autism spectrum disorder